Summary: Chromosomal translocation-generated fusion genes in childhood acute lymphoblastic leukemia (ALL) are well-known indicators of prognostic outcome. This study was conducted to establish the clinical relevance of the fusion genes distribution pattern in Mexican children with newly diagnosed ALL. Multiplex RT-PCR assays were used to detect 4 commonest fusion transcripts in 261 Mexican children with B-cell precursor ALL aged 1 to 14 years old, comparing differences in the distribution of the patients between molecular subgroups to a common collection of clinical parameters. We documented a 13% significant proportion of all patients who are more than 10 years of age, harboring fusion transcripts associated with leukocytosis and poor response to remission-induction chemotherapy, than those negative children for chimeric transcripts (P < 0.001). Most notable observation was identified a significant number of e2a-pbx1-positive patients who showed a more aggressive disease at diagnosis. As presented here, this report gives an overview of the clinical implications of the fusion gene positivity in Mexican children with ALL in the context of traditional risk stratification variables. Our data support the existence of important ethnic and geographic differences in Mexican population.
Summary: Chromosomal translocation-generated fusion genes in childhood acute lymphoblastic leukemia (ALL) are well-known indicators of prognostic outcome. This study was conducted to establish the clinical relevance of the fusion genes distribution pattern in Mexican children with newly diagnosed ALL. Multiplex RT-PCR assays were used to detect 4 commonest fusion transcripts in 261 Mexican children with B-cell precursor ALL aged 1 to 14 years old, comparing differences in the distribution of the patients between molecular subgroups to a common collection of clinical parameters. We documented a 13% significant proportion of all patients who are more than 10 years of age, harboring fusion transcripts associated with leukocytosis and poor response to remission-induction chemotherapy, than those negative children for chimeric transcripts (P < 0.001). Most notable observation was identified a significant number of e2a-pbx1-positive patients who showed a more aggressive disease at diagnosis. As presented here, this report gives an overview of the clinical implications of the fusion gene positivity in Mexican children with ALL in the context of traditional risk stratification variables. Our data support the existence of important ethnic and geographic differences in Mexican population. A cute lymphoblastic leukemia (ALL) is, in essence, a malignant hematologic disorder strongly associated with acquired chromosomal abnormalities, in particular balanced reciprocal translocations, resulting in the generation of rearranged genes who have an important role in diagnosis and prognosis. 1 In this regard, the detection of prognostic significant fusion genes by molecular technologies has been essential for the management of newly diagnosed ALL cases, helping to select the appropriate treatment to avoid excessive toxicity of the chemotherapy maintaining a high remission rate. 2 In Mexico, the incidence of childhood cancer is one of the highest in the world, of which ALL is the malignancy most commonly found. 3 Nevertheless, little is known about the clinical implications of the fusion gene positivity in Mexican children with ALL according to conventional or traditional risk stratification variables. The aim of this study was to establish the prognostic relevance of the commonest fusion transcripts distribution pattern in Mexican children with newly diagnosed ALL, without using modern minimal residual disease techniques of high economic cost that might be not available for most laboratories in developing countries with limited financial resources.
MATERIALS AND METHODS

Patients
This study was prospectively designed to study 610 consecutive cases of acute leukemia that were diagnosed and treated in 3 different public Hospitals in the period between January 2006 and December 2009. Bone marrow aspirates of untreated patients with hematologic malignancies of less than 15 years old were collected at the time of routine diagnosis procedures. The ALL diagnosis was established using the FAB classification for bone marrow blast morphology; the morphologic results were supported by cytochemical and immunophenotypic analyses. 4 [5] [6] [7] In order to test the hematological response, bone marrow evaluation was performed at day 30 of remissioninduction treatment, patients who have leukemic blast cells in bone marrow >5% were considered with poor response at induction phase and a good hematological response was defined in patients with leukemic blast cells count <5%.
Positive Controls and Primers
Bone marrow samples from patients with t(9;22), t(12;21), t(1;19), t(4;11)-containing ALL, previously identified by cytogenetics or fluorescence in situ hybridization were included as positive controls (data not shown). Primer sequences used in the multiplex PCR assay were designed using the Primer Express Software (Applied Biosystems; Foster City, CA), based on nucleotide sequence information available at the NCBI (GenBank; http://www.ncbi.nlm. nih.gov/guide/), for tel-aml1 (accession number: AF044317), e2a-pbx1 (accession number: M31522), mll-af4 (accession number: L22179), and b2-microglobulin (b2m) gene (accession number: NG_012920). The specific primers recognizing fusion transcripts were designed to amplify junction regions giving PCR products of different size. Detection of bcr-abl fused transcripts was performed on an independent reaction tube by a multiplex PCR method as has been previously reported. 8 
Multiplex PCR Assays
Total RNA was isolated from Histopaque-1077 (Sigma-Aldrich; St Louis, MO)-separated bone marrow lymphoblasts using TRIzol (Invitrogen; Grand Island, NY) reagent according to manufacturer's instructions. The integrity of RNA was examined by denaturing agarose gel electrophoresis, the 18S and 28S RNA bands were visualized by UV illumination. The RNA concentration of was determined spectrophotometrically. Two micrograms of DNase I-treated RNA were reverse transcribed in a 20 mL reaction. The reaction mixture consisted of 4 mL of 5 Â first-strand buffer [250 mM Tris-HCl (pH 8.3), 375 mM KCl, and 15 mM MgCl 2 ], 0.5 mM dNTPs, 5 mM dithiothreitol, 15 U RNase Inhibitor (Invitrogen), 250 ng random primers, and 200 U SuperScript II Reverse Transcriptase (Invitrogen), following the manufacturer's specifications. Multiplex PCR amplifications were performed using 2 mL of cDNA as template and reaction mixtures (50 mL) containing: 1 Â PCR buffer, 1.5 mM of MgCl 2 , 200 mM of each dNTP, 400 nM of each primer, and 2.5 U of Taq DNA polymerase (Invitrogen). We used the following primers: tel-aml1 5
Thirty cycles of amplification were carried out using a GeneAmp PCR System 9700 thermal cycler (Applied Biosystems; Foster City, CA). The multiplex protocol included a 3-minute incubation at 951C followed by a touchdown program that consisted of 10 cycles of 50 seconds at 941C, 50 seconds at 621C, and 1 minute at 721C; following by 10 subsequent cycles, the annealing temperature down to 21C each cycle keeping the incubation time mentioned above; after that, the annealing temperature reached 581C. A final extension of 10 minutes at 721C was performed and the tubes reactions were cooling to 41C. As mentioned above, detection of bcr-abl fused transcripts was performed as has been previously reported. 8 To verify the integrity of the isolated RNA and the correct synthesis of the cDNA, a 380-bp fragment of the b2m gene was coamplified as internal control using the following primers:
0 . Finally, the multiplex PCR products were separated by electrophoresis on a 2% agarose gel stained with ethidium bromide and visualized under UV light.
Sequence Analysis
The amplified material was separated by electrophoresis on a 1% agarose gel and extracted from the gel using a Qiaex II gel extraction kit (Qiagen; Hilden, Germany). Purified fragments were directly sequenced on both strands with fluorescent dideoxy chain terminators using the Thermo Sequenase Dye Terminator Cycle Sequencing Premix Kit according to manufacturer's instructions (Amersham, GE Healthcare Life Science; Pittsburgh, PA). Sequenced products were purified by ethanol precipitation and analyzed using an ABI 310 automated DNA sequencer (Applied Biosystems).
Statistics
Differences in the distribution of the patients between molecular subgroups to a common set of categorized clinical parameters with specific prognostic value 9-11 were analyzed by a Cox proportional hazards regression model. 12 The statistically significant clinical variables identified were confirmed by univariate analysis such as the w 2 test or the Fisher exact test when a 2Â 2 contingency table the observations of 1 or more cells is <5. Duration of hematologic remission first or event-free survival (EFS) was defined as the time from achievement of complete remission until the date of failure: early death, relapse, and induction failures such as death during induction therapy or failure to achieve complete remission on day 56 (nonresponse). Early death and nonresponse were considered failures at time 0. The MannWhitney rank-sum test was used to assess differences between the median EFS duration in the patient subgroups. Statistical analyses were performed using the SigmaStat statistical program (Jandel Scientific, SPSS; San Jose, CA) and P-value below 0.01 was considered statistically significant. diagnosis, including the first remission duration. The clinical follow-up of the patients was on October 30, 2012. Younger children than 1 year old were not eligible for its analysis. To determine the presence of the 4 commonest ALL fusion genes: tel-aml1, bcr-abl, e2a-pbx1, and mll-af4, we performed multiplex RT-PCR assays using retrotranscribed RNA obtained from lymphoblasts. Figure 1 illustrates representative results obtained by multiplex RT-PCR and authenticity of the amplification products were verified by direct sequencing of selected positive cases. As expected, obtained nucleotide sequences corresponded to junction regions of each fusion transcripts (Fig. 2) . In the subsequent multiplex PCR experiments, we found an incidence for tel-aml1 of 14.9%, followed by 7.3% for bcr-abl, 5.8% for e2a-pbx1, and 4.2% for mll-af4 (Table 1) . Statistic analysis revealed statistically significant differences in the distribution of the patients between molecular subgroups at categorized clinical variables, which are consistent with traditional risk stratification criteria: age/white blood cell count at diagnosis and response to induction treatment (Table 1) . A detailed analysis documented that the fusion gene positivity occurred in 13% of all patients, who were older than 10 years, usually tend to have leukocytosis and a poor response to remission-induction chemotherapy, in comparison with children negative for chimeric transcripts (P < 0.001). In contrast, although no statistically significant difference in the median EFS duration was found between the molecular subgroups (P > 0.001); unexpectedly, a significant number of e2a-pbx1-positive patients showed a hematologic remission duration similar at the known high-risk molecular subgroups such as bcr-abl or mll-af9, in addition, a more aggressive disease at diagnosis (Table 1) .
RESULTS
DISCUSSION
As we show, this is a large prospective study designed to obtain information on the clinical relevance of the fusion FIGURE 2. Representative results from direct sequencing using multiplex PCR products. Chromatograms show the junction regions of e1-a2, tel-aml1, e2a-pbx1, and mll-af4 fused transcripts. Arrowheads: junction regions. transcripts distribution pattern in Mexican children with newly diagnosed ALL. Therefore, the patients were stratified according to a common set of clinical parameters, compared these clinical data at presentation between the molecular subgroups (Table 1) . Interestingly, our data indicate that the age distribution of the rearranged genes is associated with unfavorable clinical characteristics for a significant proportion of older patients than 10 years, whereas those children aged 1 to 10 years was significantly better clinical outcome (P < 0.001), based on considerations of traditional risk stratification variables: age/ white blood cell count at diagnosis and response to induction treatment (Table 1) . Nevertheless, no statistically significant difference in the median EFS duration was found between the molecular subgroups (Table 1) , most notable observation was the lack of standard-risk for e2a-pbx1 13, 14 in the majority of the positive patients at this chimeric transcript, which was related with a more aggressive disease at diagnosis. We considered that the prognostic outcome discrepancy could be related to additional cytogenetic abnormalities such as intrachromosomal amplification of chromosome 21, abnormal 17p or deletion of 13q. 15 As presented here, the adverse clinical outcome in the e2a-pbx1 cases and gene rearrangement status documented in Mexican children with ALL at the time of initial diagnosis could be due to (a) environment interactions with a complex genetic component and (b) different proportions of Native American and European genetic background, which support the existence of important ethnic and geographic differences in Mexican population. These findings contrast to reports from white and South American populations, [16] [17] [18] but similar to those found for Asiatic populations, which are characterized by a lowest incidence of tel-aml1 and highest frequency of rearranged genes generally associated with poor prognosis. 19, 20 Finally, this study is of particular interest for developing countries with limited financial resources to evaluated risk stratification criteria in B-cell precursor ALL, who were treated with multiagent induction therapy, and where the application of minimal residual disease analysis cannot be used because of high cost.
